Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 191

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 191
---
 public offering.

<div align='center'>116</div>

Agreements and Arrangements With, and Compensation of, Directors and Executive Officers

Certain of our executive
officers have employment agreements with us. These agreements will terminate at the closing of this offering and will be replaced by
new employment agreements, which will contain customary provisions and representations, including confidentiality, non-competition, non-solicitation
and inventions assignment undertakings by the executive officers. None of our employment or service provider agreements contain any terms
providing for severance benefits. Under current applicable Israeli employment laws, we may not be able to enforce (either in whole or
in part) covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of
our former employees. See “Management—Compensation of Executive Officers and Directors”. In addition, certain of our
other executive officers have service provider agreements with us pursuant to which they are engaged by us as independent contractors.
These service provider agreements prohibit such executive officers from engaging in activities that would present a conflict of interest
to us or would involve providing services to our competitors. See “Management— Engagement Agreements with Executive Officers”
for additional information.

Investors’ Rights Agreement

On February 5, 2016, we entered
into an investors’ rights agreement, or the IRA, with several of our shareholders, who hold in the aggregate a total
of 946,392 Ordinary Shares. Pursuant to the IRA, the shareholders have a right to require that we register such 946,392 Ordinary Shares
under the Securities Act under specific circumstances and will have incidental registration rights as described below.

Demand Registration Rights

At any time following nine
(9) months after the closing of this offering, subject to any lock-up agreements, at the request of the holders of a majority of: (i)
any Ordinary Shares of the Company issued upon conversion of any Series A Preferred Shares, Series B Preferred Shares, Series C Preferred
Shares, Series D-1 Preferred Shares and Series D-2 Preferred Shares, or issuable upon conversion of any Preferred Shares; (ii) all Ordinary
Shares that the holders of the Preferred Shares may purchase or receive pursuant to their preemptive rights, rights of first refusal,
anti-dilution rights and otherwise, and all Ordinary Shares issued on conversion or exercise of other securities so purchased, including
upon conversion of the Preferred Shares, and (iii) any Ordinary Shares of the Company issued (or issuable